S&P 500
5,939.17
-0.4%
-24.43
DJI
42,687.12
-0.2%
-104.95
NASDAQ
$19,153.32
-0.3%
-$62.14
Bitcoin
106,204.00
+0.8%
+803.59
AAPL
$206.37
-1.2%
-$2.41
AMZN
$203.82
-1.1%
-$2.34
GOOG
$166.62
-0.7%
-$1.25
META
$636.01
-0.7%
-$4.42
MSFT
$455.82
-0.7%
-$3.05
NVDA
$134.10
-1.1%
-$1.47
TSLA
$353.17
+3.2%
+$11.08
CytoDyn (OTC: CYDY)
$0.39
(1.6%)
$0.01
Price as of May 20, 2025, 12:54 p.m. ET
CytoDyn Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CytoDyn Company Info
CytoDyn, Inc. is a clinical-stage biotechnology company, which engages in the development of innovative treatments for multiple therapeutic indications based on leronlimab. Its product include HIV, Cancer, graft-versus-host disease (GVHD), and COVID-19. The company was founded by Allen D. Allen on May 2, 2002 and is headquartered in Vancouver, WA.
News & Analysis
Featured Article
3 Biotechs to Avoid Like the Plague in July
Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.
Zhiyuan Sun | Jul 6, 2021
Featured Article
What's Behind This Wild-Card Coronavirus Stock?
Failure is not an option for this small-cap biotech developing a COVID-19 treatment.
Zhiyuan Sun | Jun 8, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.